Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Glaukos Submits FDA Application for Epioxa Therapy
Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…
EYLEA HD Succeeds in Phase 3 RVO Trial
Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (aflibercept 8 mg) has met its primary endpoint, marking a significant advancement in the treatment of retinal vein occlusion (RVO). About the QUASAR Trial The QUASAR trial…
Aurion’s AURN001 Shows Positive Phase 1/2 Results
Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN001, an allogeneic cell therapy product candidate for treating corneal edema secondary to corneal endothelial dysfunction. These results highlight the therapy’s potential as a groundbreaking treatment…
2023 Recap: Top 15 Research in Ophthalmology
2024 Recap is here! Click to review:Top 10 Breakthroughs in Ophthalmology Research In the fast-evolving landscape of ophthalmology research, 2023 has proven to be a pivotal year marked by groundbreaking discoveries and innovation. From revolutionary cell replacement therapies to novel…
Top 12 Ophthalmic Drugs That Received FDA Approval
2024 Recap is here! Click to review:Top 8 FDA Approvals in Opthalmology In a series of groundbreaking developments, the FDA has approved a range of innovative drugs in 2023, heralding a new era in ophthalmic treatments. Here’s an in-depth look…
VisiRose Unveils Non-Invasive Therapy for Keratitis
VisiRose, a newly established company formed in collaboration with Provectus Biopharmaceuticals and the Bascom Palmer Eye Institute (BPEI) at the University of Miami Miller School of Medicine, is advancing the development of Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This…
First Inverted Meniscus Optics IOLs by Voptica
*This exclusive article is sponsored by Voptica. The opinions expressed in this article are the sponsor’s own. Intraocular lenses (IOLs) designs are constantly evolving to improve patients’ vision needs. Trifocal diffractive IOLs are designed to achieve good visual acuity at…
Yamane Technique – Intrascleral IOL Fixation
In cataract surgery, the optimal outcome involves implanting an intraocular lens (IOL) within the capsular bag. However, complications such as posterior capsule rupture, congenital lens anomalies, or traumatic injuries can leave patients without adequate capsular support, resulting in aphakia—a condition…
ESCRS 2024 Exclusive Insights: iNovation Day in Focus
The European Society of Cataract and Refractive Surgeons (ESCRS) is gearing up for an innovative event with its iNovation® Day in Barcelona, Spain, on Friday 6 September 2024 at the Fira Barcelona Gran Via. Scheduled to be held prior to…